Immunomedics Develops Novel Dual System for Tumor Detection and Imaging

Immunomedics Develops Novel Dual System for Tumor Detection and Imaging

-- Pretargeting System Allows Dual Nuclear/Fluorescence Imaging During Cancer
                                  Surgery --

             -- Results Reported at SNMMI 2013 Annual Meeting --

VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics,
Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced the
development of a pretargeting system that can detect and optically image a
tumor during surgery. Results from this preclinical study were presented by
Dr. Mark Rijpkema of the Department of Nuclear Medicine, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands.

While tumor detection with specific radiotracers may be a useful tool for
accurate localization and resection during surgery, these procedures could
benefit from the addition of an optical tracer, since this may allow for more
accurate delineation of the tumor and resection margins. Both tracers in such
a dual modality approach need to show high specificity and a high
tumor-to-background ratio (TBR).

The pretargeting system that the Company is pursuing involves the bispecific
antibody, TF2, which targets the carcinoembryonic antigen (CEA), specifically
CEACAM5, expressed in many human cancers, including breast, colorectal and
lung cancer, and which is also being used in its IMMU-130 antibody-drug
conjugate in clinical trials. Created by the Company's proprietary
DOCK-AND-LOCK™ method, the bispecific antibody is currently in a number of
clinical trials for pretargeted immunoPET imaging and radioimmunotherapy of
patients with CEA-expressing cancers.

The other component of the pretargeting system is a small peptide bearing both
the fluorescent dye, IRdye800CW, and a linker called DOTA for radiolabeling.
Designated as RDC-018, this new peptide was derived from an earlier peptide,
IMP288, that has been used successfully in pretargeting with a number of
radioisotopes such as indium-111 (^111In), yttrium-90, lutetium-177 and

The goal of this preclinical study was to assess the potential utility of this
peptide for cancer detection by both optical (light) and radionuclide imaging,
starting with an assessment of the radiolabeling procedure for RDC-018, and
leading into in vivo biodistribution and tumor localization properties in a
pretargeting setting compared to the ^111In-IMP288. Animals bearing
subcutaneous CEA-positive human colonic tumors and CEA-negative human renal
cell tumors were used.

Biodistribution study of the RDC-018 peptide showed specific CEA-expressing
tumor targeting with clearance via the kidneys similar to IMP288. Despite
differences in renal uptake, RDC-018, with its ability to be imaged by both
scintigraphic and optical methods, provided high tumor targeting and excellent
TBR, illustrating the feasibility of this dual modality imaging approach.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases. We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or
toxins, in each case to create highly targeted agents.Using these
technologies, we have built a pipeline of therapeutic product candidates that
utilize several different mechanisms of action.We also have a majority
ownership in IBC Pharmaceuticals, Inc., which is developing a novel
DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and
multifunctional antibodies, and a new method of delivering imaging and
therapeutic agents selectively to disease, especially different solid cancers
(colorectal, lung, pancreas, etc.), by proprietary, antibody-based,
pretargeting methods. We believe that our portfolio of intellectual property,
which includes approximately 223 active patents in the United States and more
than 400 foreign patents, protects our product candidates and
technologies.Our strength in intellectual property has resulted in the top-10
ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology
and Pharmaceuticals category.For additional information on us, please visit
our website at The information on our website does not,
however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials, out-licensing arrangements (including the timing and amount of
contingent payments), forecasts of future operating results, potential
collaborations, and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed
or implied herein. Factors that could cause such differences include, but are
not limited to, risks associated with any cash payment that the Company might
receive in connection with a sublicense involving a third party and UCB, which
is not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our dependence
on our licensing partners for the further development of epratuzumab and
veltuzumab for non-cancer indications, competitive risks to marketed products
and availability of required financing and other sources of funds on
acceptable terms, if at all, as well as the risks discussed in the Company's
filings with the Securities and Exchange Commission.The Company is not under
any obligation, and the Company expressly disclaims any obligation, to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.